Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. It seems that President Trump’s plan to address U.S. drug prices isn’t going away any time soon. Read on to see what’s happening in D.C. on that front.

The need-to-know this morning

Areteia Therapeutics said its experimental drug, a twice-daily pill called dexpramipexole, improved lung function in patients with a type of asthma driven by an increase of white blood cells. The outcome achieved the primary goal of a placebo-controlled Phase 3 study. Privately held Areteia is conducting two more Phase 3 studies of dexpramipexole in asthma.

Hill staffers mull Trump’s drug pricing plan

Congressional staffers and health policy experts from major thi

See Full Page